
Type 2 Diabetes
Latest News
CME Content



Ask patients to reframe the readings as a call to action, a signal to tweak, to fine-tune.

An increased duration of lactation was associated with a 25% to 47% relative reduction in diabetes incidence.

A rare genetic condition has been linked to the development of both diabetes and insulinomas in a single family.

Higher rates of stillbirths, the need for emergency Caesarean sections, and infant mortality have all been associated with both type 1 and type 2 diabetes

The study is the first of 3 in the International Diabetes Closed Loop trial, funded by the National Institute of Health.


The first-to-market hybrid closed loop CGM and "smart" insulin pens are 2 of our picks for 2017’s best tech advances in diabetes management.

ShugaTrak, Glucose Buddy, OnTrack -- 3 of the 5 apps we highlight that are designed to make diabetes monitoring seamless for all.

OZEMPIC, a GLP-1 receptor agonist, was tested in 2-year cardiovascular outcome trials.

Alex Azar's nomination for secretary of Health and Human Services has been met with controversy due to his ties to the pharmaceutical industry.

Fetuses of obese mothers have higher weight, larger head circumferences and some longer bones, according to a new study.

Combining ACE inhibitors with a statin was unsuccessful to change albumin-to-creatinine ratio in adolescent patients with T1D.

Stay updated on the biggest headlines with MDNN from November 10, 2017.

Use of the Lark AI Health Coach resulted in a mean weight loss of 2.38% of baseline weight.

Rivaroxaban is the only Factor Xa inhibitor demonstrating superior efficacy in reducing recurrent VTE after initial treatment.

The FDA advisory committee voted 16-0 in favor semaglutide's approval.

What about those patients who fall into the "gray zone"?

The Certified Nurse Practicioner from the Henry Ford Medical Center also weighs in the best advice to avoid cardiovascular disease.


Gregg Fonarow, MD; David Aguilar, MD; Rob Mentz, MD; and James Januzzi, MD, discuss the unexpected and exciting use of SGLT-2 inhibitors to treat heart failure.

Rob Mentz, MD, of Duke University Medical School, discusses the CANVAS trial and the pursuit of using SGLT-2 inhibitors to treat heart failure.

The drug, produced by Sanofi, was granted approval based on the physiochemical, non-clinical, and clinical similarity to another, already approved insulin lispro injection.

In just 9 days of limited fructose consumption, both liver fat concentration and de novo lipogensis decreased.








































































